The clinical utility of 18F-FDG PET-CT for detection of bone marrow infiltration in lymphoma

doi:10.3760/cma.j.issn.1673422X.2016.08.019

Abstract

Abstract: Bone marrow infiltration in lymphoma is crucial to the disease diagnosis, staging, treatment options and prognostic evaluation. Although bone marrow biopsy is the main detecting method, it has high false negative rate. At present, 18F-fluorodeoxyglucose positron emission tomography-computed tomography (18F-FDG PET-CT) technology which is integrating morphological characteristics with metabolic function provides a new way for the diagnosis, staging and prognostic evaluation of bone marrow infiltration in lymphoma due to its advantages of high sensitivity, high specificity and functional image.

Key words: ymphoma, Bone marrow, Fluod deoxyglucose F18, Positronemission tomography

Wu Yuan, Liu Xiaolan, Su Liping. The clinical utility of 18F-FDG PET-CT for detection of bone marrow infiltration in lymphoma[J]. Journal of International Oncology, 2016, 43(8): 634-637.

References

［1］ El-Galaly TC, D′amore F, Mylam KJ, et al. Routine bone marrow biopsy has little or no therapeutic consequence for positron emission tomography/computed tomographystaged treatmentnaive patients with hodgkin lymphoma［J］. J Clin Oncol, 2012, 30(36): 4508-4514. DOI: 10.1200/JCO.2012.42.4036. ［2］ Hutchings M. The role of bone marrow biopsy in hodgkin lymphoma staging: "to be, or not to be, that is the question"?［J］. Leuk Lymphoma, 2012, 53(4): 523-524. DOI: 10.3109/10428194.2012.659737. ［3］ Alavi A, Shrikanthan S, Aydin A, et al. Fluorodeoxyglucose-positron-emission tomography findings in mantle cell lymphoma［J］. Clin Lymphoma Myeloma Leuk, 2011, 11(3): 261-266. DOI: 10.1016/j.clml.2011.03.013. ［4］ Kostakoglu L, Cheson BD. Current role of FDG PET/CT in lymphoma［J］. Eur J Nucl Med Mol Imaging, 2014, 41(5): 1004-1027. DOI: 10.1007/s00259-013-2686-2. ［5］ Muzahir S, Mian M, Munir I, et al. Clinical utility of 18F FDG-PET/CT in the detection of bone marrow disease in hodgkin′s lymphoma［J］. Br J Radiol, 2012, 85(116): e490-496. DOI: 10.1259/bjr/29583493. ［6］汤日杰, 桂思, 李建生, 等. 18F-FDG PET/CT与大范围弥散磁共振成像评价非霍奇金淋巴瘤骨髓浸润的对比研究［J］. 中华血液学杂志, 2014, 35(3): 231-235. DOI: 10.3760/cma.j.issn.0253-2727.2014.03.011. ［7］ Adams HJ, Kwee TC, Vermoolen MA, et al. Whole-body MRI for the detection of bone marrow involvement in lymphoma: prospective study in 116 patients and comparison with FDG-PET［J］. Eur Radiol, 2013, 23(8): 2271-2278. DOI: 10.1007/s00330-013-2835-9. ［8］ Casulo C, Sch-der H, Feeney J, et al. 18F-fluorodeoxyglucose positron emission tomography in the staging and prognosis of T cell lymphoma［J］. Leuk Lymphoma, 2013, 54(10): 2163-2167. DOI: 10.3109/10428194.2013.767901. ［9］ Adams HJ, Kwee TC, De Keizer B, et al. Systematic review and meta-analysis on the diagnostic performance of FDG-PET/CT in detecting bone marrow involvement in newly diagnosed hodgkin lymphoma: is bone marrow biopsy still necessary?［J］. Ann Oncol, 2014, 25(5): 921-927. DOI: 10.1093/annonc/mdt533. ［10］ Adams HJ, Kwee TC, De Keizer B, et al. FDG PET/CT for the detection of bone marrow involvement in diffuse large B-cell lymphoma: systematic review and metaanalysis［J］. Eur J Nucl Med Mol Imaging, 2014, 41(3): 565-574. DOI: 10.1007/s00259-013-2623-4. ［11］ Pakos EE, Fotopoulos AD, Ioannidis JP. 18F-FDG PET for evaluation of bone marrow infiltration in staging of lymphoma: a meta-analysis［J］. J Nucl Med, 2005, 46(6): 958-963. ［12］ Paone G, Itti E, Haioun C, et al. Bone marrow involvement in diffuse large B-cell lymphoma: correlation between FDG-PET uptake and type of cellular infiltrate［J］. Eur J Nucl Med Mol Imaging, 2009, 36(5): 745-750. DOI: 10.1007/s00259-008-1021-9. ［13］ Sehn LH, Scott DW, Chhanabhai M, et al. Impact of concordant and discordant bone marrow involvement on outcome in diffuse large B-cell lymphoma treated with R-CHOP［J］. J Clin Oncol, 2011, 29(11): 1452-1457. DOI: 10.1200/JCO.2010.33.3419. ［14］ Khan AB, Barrington SF, Mikhaeel NG, et al. PET-CT staging of DLBCL accurately identifies and provides new insight into the clinical significance of bone marrow involvement［J］. Blood, 2013, 122(1): 61-67. DOI: 10.1182/blood-2012-12-473389. ［15］ Wu X, Pertovaara H, Korkola P, et al. Correlations between functional imaging markers derived from PET/CT and diffusion-weighted MRI in diffuse large B-cell lymphoma and follicular lymphoma［J］. PLoS One, 2014, 9(1): e84999. DOI: 10.1371/journal.pone.0084999. ［16］ Takahashi T, Minato M, Tsukuda H, et al. Successful treatment of intravascular large B-cell lymphoma diagnosed by bone marrow biopsy and FDG-PET scan［J］. Intern Med, 2008, 47(10): 975-979. ［17］ Pelosi E, Penna D, Deandreis D, et al. FDG-PET in the detection of bone marrow disease in hodgkin′s disease and aggressive non-hodgkin′s lymphoma and its impact on clinical management［J］. Eur J Nucl Med Mol Imaging, 2008, 52(1): 9-16. ［18］ Weiler-Sagie M, Kagna O, Dann EJ, et al. Characterizing bone marrow involvement in hodgkin′s lymphoma by FDG-PET/CT［J］. Eur J Nucl Med Mol Imaging, 2014, 41(6): 1133-1140. DOI: 10.1007/s00259-014-2706-x. ［19］乔文礼, 赵晋华, 王椿, 等. 18F-FDG符合探测显像与CT显像在淋巴瘤分期和疗效评价中的比较［J］. 中华肿瘤杂志, 2007, 29(7): 536-539. DOI: 10.3760/j.issn:02533766.2007.07.014. ［20］ Berthet L, Cochet A, Kanoun S, et al. In newly diagnosed diffuse large B-cell lymphoma, determination of bone marrow involvement with 18F-FDG PET/CT provides better diagnostic performance and prognostic stratification than does biopsy［J］. J Nucl Med, 2013, 54(8): 1244-1250. DOI: 10.2967/jnumed.112.114710.

[1]	Yin Yunyan, Li Hui, Li Yuchen, Hui Hui, Xu Jingyan. Clinical application of histone deacetylase inhibitors in non-Hodgkin lymphoma [J]. Journal of International Oncology, 2022, 49(8): 499-504.
[2]	Wang Liuxue, Xi Xiaoping, Liu Jingjing, Shen Guomin, Yang Haiping. Research progress of metformin in non-Hodgkin lymphoma [J]. Journal of International Oncology, 2022, 49(7): 436-440.
[3]	Guo Yiwei, Liu Aichun. Treatment of EB virus positive diffuse large B cell lymphoma [J]. Journal of International Oncology, 2021, 48(7): 385-388.
[4]	Li Qiao'er, Zou Liqun. Stratified therapeutic choices in elderly patients with diffuse large B-cell lymphoma [J]. Journal of International Oncology, 2021, 48(5): 317-320.
[5]	Chen Xi, Mu Dan, Yan Qin, Liu Wenjun. Bone marrow microenvironment and differentiation of leukemia cells [J]. Journal of International Oncology, 2021, 48(3): 189-192.
[6]	Qiao Wei, Song Teng, Chen Xinrui, Wang Huaqing. Effect of excessive activation of PI3K signaling pathway on the prognosis of patients with non-Hodgkin lymphoma and the efficacy of targeted drugs [J]. Journal of International Oncology, 2021, 48(2): 121-124.
[7]	Chen Lina, Guo Zhi, Liu Xuanyong, Chen Xiao, Zhang Yihuizhi, Li Xumian, Wei Liya, Wang Yueqiao, Xie Jing. Application study of EAC mobilization scheme in autologous hematopoietic stem cell transplantation of lymphoma [J]. Journal of International Oncology, 2021, 48(11): 666-672.
[8]	Xu Lei, Dai Jing, Zhang Qian, Zhang Wenli, Li Jinmeng, Zhang Hongyu. Clinical analysis of 93 cases of adult patients with acute lymphoblastic leukemia [J]. Journal of International Oncology, 2020, 47(9): 535-541.
[9]	Yang Lei, Zhang Chuanyu, Zhang Zaixian, Liu Huan. Radiogenomics in non-small cell lung cancer [J]. Journal of International Oncology, 2020, 47(9): 555-559.
[10]	Zhao Ke, Wang Huaqing. Progress of new drugs on relapsed/refractory peripheral T-cell lymphoma [J]. Journal of International Oncology, 2020, 47(6): 321-326.
[11]	Qi Fei, Dong Mei. Clinical characteristics and survival analysis of extra-upper aerodigestive tract extranodal NK/T-cell lymphoma [J]. Journal of International Oncology, 2020, 47(3): 157-163.
[12]	Chai Yue, Dong Mei. Prognostic role and mechanisms of abnormal coagulation system in lymphoma [J]. Journal of International Oncology, 2020, 47(10): 637-640.
[13]	Guo Jianlin, Zhang Chuanyu, Yu Hualong, Zhang Zaixian. Progress of radiogenomics in lung cancer [J]. Journal of International Oncology, 2019, 46(9): 544-547.
[14]	Sun Ye, Sheng Lixia, Ouyang Guifang. MicroRNAs and diffuse large B cell lymphoma [J]. Journal of International Oncology, 2019, 46(9): 566-569.
[15]	Xiang Mingyue, Wang Lili, Han Dali. Progress of treatment for primary mediastinal B-cell lymphoma [J]. Journal of International Oncology, 2019, 46(8): 505-508.